UAMY Q1: DLA Progress, But Revenue Still Elusive

What happened

United States Antimony reported Q1 2026 revenue of $6.8 million (flat y/y) and a net loss of $11.3 million, including $9.3 million in non-cash items. The company achieved $12.8 million in Department of War grant milestones and completed the first two delivery notices under its $245 million DLA contract, yet did not disclose any DLA revenue recognition—consistent with last year's pattern. Post-quarter, it raised $48.6 million in equity at an average of $11.57 per share, bolstering liquidity. Management reiterated full-year 2026 revenue guidance of $125 million, implying a steep ramp from current run-rate. The operational highlights show execution progress, but the absence of recognized DLA revenue and widening losses underscore that the 'headline-to-cash' conversion remains unproven.

Implication

The equity raise and grant funding provide a path to scale, but the investment thesis hinges on demonstrated DLA acceptance and stable Thompson Falls output. Until these are visible in filings, the stock remains a high-risk speculative play with no margin of safety at current valuation.

Thesis delta

The Q1 report confirms early DLA delivery and grant milestones, shifting the narrative from 'contracts secured' to 'execution started'. However, the lack of recognized DLA revenue and widening net loss keep the core thesis unchanged: the market must wait for acceptance-driven revenue and capacity proof. The equity raise reduces balance sheet risk but dilutes existing holders, leaving the risk/reward unattractive until tangible earnings materialize.